Male Pattern Baldness

Southern Medical Journal

Volumn 93, Issue 7, 2000, Pages 657-662

  Hogan, Daniel J ^a   Chamberlain, Matthew ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FINASTERIDE; MINOXIDIL; STEROID 5ALPHA REDUCTASE; VASODILATOR AGENT;

ALOPECIA; CLASSIFICATION; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HAIR; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MENTAL DISEASE; ONSET AGE; REVIEW;

ADMINISTRATION, CUTANEOUS; AGE OF ONSET; ALOPECIA; CORONARY DISEASE; ENZYME INHIBITORS; FINASTERIDE; HAIR; HUMANS; MALE; MENTAL DISORDERS; MINOXIDIL; TESTOSTERONE 5-ALPHA-REDUCTASE; VASODILATOR AGENTS;

EID: 0034222977     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200093070-00003     Document Type: Article

References (51)

1. Passchier J, Rijpma SE, Dutree-Meulenberg RO, et al: Why men with hair loss go to the doctor. Psychol Rep 1989; 65:323-330
2. Bergfeld WF: Androgenetic alopecia: an autosomal dominant disorder. Am J Med 1995; 98:95S-98S
3. Kuster W, Happle R: The inheritance of common baldness: Two B or not Two B? J Am Acad Dermatol 1984; 11:921-926
4. Ellis JA, Stebbing M, Harrap SB: Genetic analysis of male pattern baldness and the 5 alpha-reductase genes. J Invest Dermatol 1998; 110:849-853
5. Imperato-McGinley J, Guerrero L, Gauatier T, et al: Steroid 5 α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186:1213-1215
6. Thigpen AE, Silver RI, Guileyardo JM, et al: Tissue distribution and ontogeny of steroid 5 alpha-reductase isoenzyme expression. J Clin Invest 1993; 92:903-910
7. Bayne EK, Flanagan J, Azzolina B, et al: Immunolocalization of type 2 5 α-reductase in human hair follicles (Abstract). J Invest Dermatol 1997; 108:651
8. Bingham KD, Shaw DA: The metabolism of testosterone by human male scalp skin. J Endocrinol 1993; 57:111-121
9. Whiting DA: Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993; 128:755-763
10. Ishino A, Uzuka M, Tsuji Y, et al: Progressive decrease in hair diameter in Japanese with male pattern baldness. J Dermatol 1997; 24:758-764
11. Jaworsky C, Kligman AM, Murphy GF: Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol 1992; 127:239-246
12. Rushton DH, Ramsay ID, Norris MJ, et al: Natural progression of male pattern baldness in young men. Clin Exp Dermatol 1991; 16:88-92
13. Setty LR: Hair pattern of the scalp of white and Negro males. Am J Phys Anthropol 1970; 33:40-55
14. Bertolino AP: Clinical hair loss: diagnosis and treatment. J Dematol 1993; 20:604-610
15. Headington JT: Transverse microscopic anatomy of the human scalp. Arch Dermatol 1984; 120:449-456
16. Hamilton JB: Patterned loss of hair in man: types and incidence. Ann NY Acad Sci 1951; 53:708-728
17. Norwood OT: Male pattern baldness: classification and incidence. South Med J 1975; 68:1359-1365
18. Ludwig E: Classification of the types of androgenetic alopecia (common baldness) arising in the female sex. Br J Dermatol 1977; 97:249-254
19. Simpson N: The management of AGA in women. J Dermatol Treatment 1989; 1:107-109
20. Cash TF: The psychological effects of AGA in men. J Am Acad Dermatol 1992; 26:926-931
21. Wells PA, Willmoth T, Russell RJ: Does fortune favor the bald? psychological correlates of hair loss in males. Br J Psychol 1995; 86:337-344
22. Butler J, Pryor B, Grieder M: Impression formation as a function of male baldness. Percep Mot Skills 1998; 96:347-350
23. Gleeson MJ, Connoly J, Grainger R: Self castration as treatment for alopecia. Br J Urol 1993; 71:614-615
24. Oh BR, Kim SJ, Moon JD, et al: Association of benign prostatic hyperplasia with male pattern baldness. Urology 1998; 51:744-748
25. Lesko SM, Rosenberg L, Shapiro S: A case-control study of baldness in relation to myocardial infarction in men. JAMA 1993;269:998-1003
26. Ford ES, Freedman DS, Byers T: Baldness and ischemic heart disease in a national sample of men. Am J Epidemiol 1996; 143:651-657
27. Herrera CR, D'Agostino RB, Gerstman BB, et al: Baldness and coronary heart disease rates in men from the Framingham Study. Am J Epidemiol 1995; 142:828-833
28. Schnohr P, Lange P, Nyboe J, et al: Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City heart study. Am Heart J 1995; 130:1003-1010
29. Trevisan M, Farinaro E, Krogh V, et al: Baldness and coronary heart disease risk factors. J Clin Epidemiol 1993; 46:1213-1218
30. Savin RC, Alton AV: Minoxidil: update on its clinical role. Dermatol Clin 1993; 11:55-64
31. Lachgar S, Chaveron M, Gall Y, et al: Minoxidil upregulates the expression of vascular endothelial growth factor in hair dermal papilla cells. Br J Dermatol 1988; 138:407-411
32. Kurata S, Uno H, Allen-Hoffman BL: Effects of hypertrichotic agents on follicular and nonfollicular cells in vitro. Skin Pharmacol 1996; 9:3-8
33. Product Monograph for Rogaine Extra Strength for Men. Upjohn, 1998
34. Trancik RJ: Update on topical minoxidil in hair loss. Presented at the annual meeting of American Academy of Dermatology, Orlando, Fla, February 27, 1998
35. Funk JO, Maibach HI: Propylene glycol dermatitis: re-evaluation of an old problem. Contact Dermatitis 1994; 31:236-241
36. Whitmore SE: The importance of proper vehicle selection in the detection of minoxidil sensitivity. Arch Dermatol 1992; 128:653-656
37. Price VH, Menefee E: Quantitative estimation of hair growth: comparative changes in weight and hair count with 5% and 2% minoxidil, placebo and no treatment. Hair Research for the Next Millennium. Van Neste DJJ, Randall VA (eds). New York City, NY, Elsevier Science, 1996, pp 67-71
38. Chen W, Zouboulis CC, Orfanos CE: The 5-alpha reductase system and its inhibitors. Dermatology 1996; 193:177-184
39. Product monograph, Propecia, West Point, Pa, Merck, 1998
40. Roberts J, Hordinsky M, Olsen E, et al: The effects of finasteride on postmenopausal women with androgenetic alopecia (Abstract). Read at The Society of Investigative Dermatology, Cologne, Germany, May 7, 1998
41. Andriole GL, Guess HA, Epstein JI, et al: Treatment of finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blinded, placebo-controlled clinical trial: PLESS Study Group, Proscar long-term efficacy and safety study. Urology 1998; 52:195-202
42. Kaufman KD, Olsen EA, Whiting D, et al: Finasteride in the treatment of men with androgenetic alopecia, finasteride male pattern hair loss study group. J Am Acad Dermatol 1998; 39:578-589
43. Whiting D: Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men. Presented at Second Intercontinental Meeting of Hair Research Societies, Washington, DC, November 5-7, 1998
44. Diani AR, Mulholland MJ, Shull KL, et al: Hair growth effects of oral administration of finasteride, a steroid 5-alpha reductase inhibitor alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 1992; 74:345-350
45. Walsh DS, Dunn CL, James WD: Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride. Arch Dermatol 1995; 131:1373-1375
46. Savin RC: Evaluating Androgenetic Alopecia in Male and Female Patients. Kalamazoo, Mich, The Upjohn Company, 1994
47. Amichia B, Grunwald MH, Sobel R: 5-Alpha reductase inhibitors - new hope in dermatology. (Commentary). Int J Dermatol 1997; 36:182-184
48. Sawaya ME: Clinical updates in hair. Dermatol Clin 1997; 15:37-43
49. diSalle E, Giudici D, Radice A, et al: PNU 157706, novel dual type I and II 5 alpa-reductase inhibitor. J Ster Biochem Mol Biol 1998; 64:179-186
50. Schwartz JI, Tanaka WK, Wang DZ, et al: MK-386, an inhibitor of 5 alpha-reductase type I reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. J Clin Endocrinol Metab 1997; 82:1373-1377
51. Sawaya ME: Novel agents for the treatment of alopecia. Semin Cutan Med Surg 1998; 17:276-283